Abstract | BACKGROUND: METHODS: Patients were administered aflibercept injections once a month for 3 months followed by once every 2 months in the first year. After year 1, treatment with aflibercept monotherapy as indicated or in combination with PDT at the retinal specialist's discretion. Only cases completing the three-year follow-up were included. Regression analysis with visual acuity and macular atrophy at year 3 was performed for the dependent variable. RESULTS: Of the 292 eyes, 15 eyes underwent rescue PDT following year 1. The best-corrected visual acuity (logarithm of minimal angle of resolution, mean/Snellen equivalent ± SD) was 0.35 (20/45) ± 0.38, 0.23 (20/30) ± 0.36, 0.26 (20/35) ± 0.38, and 0.31 (20/40) ± 0.42 at baseline, year 1, year 2, and year 3, respectively. Multiple regression analysis revealed that the rescue PDT was significantly associated with macular atrophy and poor visual outcome at year 3 (odds ratio = 1.2, p < 0.001; β = 0.23, p = 0.0029, respectively). CONCLUSIONS: The visual outcome in eyes with nAMD retained baseline levels at year 3; however, patients treated with rescue PDT developed macular atrophy more frequently and poor visual outcomes.
|
Authors | Miyo Yoshida, Akio Oishi, Masahiro Miyake, Sotaro Ooto, Hiroshi Tamura, Manabu Miyata, Ayako Takahashi, Masayuki Hata, Kenji Yamashiro, Akitaka Tsujikawa |
Journal | Photodiagnosis and photodynamic therapy
(Photodiagnosis Photodyn Ther)
Vol. 38
Pg. 102745
(Jun 2022)
ISSN: 1873-1597 [Electronic] Netherlands |
PMID | 35123015
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022. Published by Elsevier B.V. |
Chemical References |
- Angiogenesis Inhibitors
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Atrophy
(chemically induced, complications, drug therapy)
- Fluorescein Angiography
- Humans
- Intravitreal Injections
- Macular Degeneration
(drug therapy)
- Photochemotherapy
(methods)
- Tomography, Optical Coherence
- Treatment Outcome
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
|